HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment (HLA-G-COVID)

Hopital Foch

Status: Completed

Conditions: Covid19

Treatments: Other: Baseline blood sample; Other: Baseline and during hospitalization blood samples

Study type: Interventional

Funder types: Other

Identifiers

NCT04613297

2020_0082

Details and patient eligibility

About

The aim of the research is to study the immune checkpoint linked to the HLA-G molecule in the dysregulation of the control of COVID-19 infection.

Full description

Single-center, prospective, open-ended, interventional study with minimal risks and constraints. Patients will be divided into 3 groups: patients not infected with COVID-19, patients infected with COVID-19 not hospitalized, patients infected with COVID-19 hospitalized.

Enrollment: 91 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient with possible or confirmed infection by COVID-19

Exclusion criteria

• Patient without liberty or guardianship

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

91 participants in 3 patient groups

COVID-19 uninfected patients

Other group

Description:

Patient with negative PCR result

Treatment:

Other: Baseline blood sample

non-hospitalized COVID-19 infected patients

Other group

Description:

Patient with positive PCR result who does not require hospitalization for COVID-19

Treatment:

Other: Baseline blood sample

hospitalized COVID-19 infected patients

Other group

Description:

Patient with positive PCR who require hospitalization for COVID-19

Treatment:

Other: Baseline and during hospitalization blood samples